These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3297578)

  • 21. Effects of insulin therapy with continuous subcutaneous insulin infusion (CSII) in diabetic patients: comparison with multi-daily insulin injections therapy (MDI).
    Derosa G; Maffioli P; D'Angelo A; Salvadeo SA; Ferrari I; Fogari E; Mereu R; Gravina A; Palumbo I; Randazzo S; Cicero AF
    Endocr J; 2009; 56(4):571-8. PubMed ID: 19352055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence of hypoglycemic episodes in diabetic patients under continuous subcutaneous insulin infusion and intensified conventional insulin treatment: assessment by means of semiambulatory 24-hour continuous blood glucose monitoring.
    Arias P; Kerner W; Zier H; Navascués I; Pfeiffer EF
    Diabetes Care; 1985; 8(2):134-40. PubMed ID: 3888562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Difference in insulin usage patterns with pubertal development in children with type 1 diabetes during transition from multiple daily injections to continuous subcutaneous insulin infusion (CSII) and through the CSII treatment.
    Shashaj B; Sulli N
    Diabetes Technol Ther; 2009 Dec; 11(12):767-74. PubMed ID: 20001677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glycemic control and perinatal outcomes of pregnancies complicated by type 1 diabetes: influence of continuous subcutaneous insulin infusion and lispro insulin.
    Chico A; Saigi I; García-Patterson A; Santos MD; Adelantado JM; Ginovart G; de Leiva A; Corcoy R
    Diabetes Technol Ther; 2010 Dec; 12(12):937-45. PubMed ID: 21128840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human regular U-500 insulin via continuous subcutaneous insulin infusion versus multiple daily injections in adults with type 2 diabetes: The VIVID study.
    Grunberger G; Bhargava A; Ly T; Zisser H; Ilag LL; Malone J; Fan L; Zhang S; Johnson J
    Diabetes Obes Metab; 2020 Mar; 22(3):434-441. PubMed ID: 31865633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII.
    Hirsch IB; Bode BW; Garg S; Lane WS; Sussman A; Hu P; Santiago OM; Kolaczynski JW;
    Diabetes Care; 2005 Mar; 28(3):533-8. PubMed ID: 15735183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined continuous subcutaneous insulin infusion and multiple subcutaneous injections in type I diabetic patients.
    Schiffrin A; Belmonte M
    Diabetes Care; 1981; 4(6):595-600. PubMed ID: 6751734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does the timing of insulin pump therapy initiation after type 1 diabetes onset have an impact on glycemic control?
    Shalitin S; Lahav-Ritte T; Lebenthal Y; Devries L; Phillip M
    Diabetes Technol Ther; 2012 May; 14(5):389-97. PubMed ID: 22283639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Higher rates of large-for-gestational-age newborns mediated by excess maternal weight gain in pregnancies with Type 1 diabetes and use of continuous subcutaneous insulin infusion vs multiple dose insulin injection.
    Hauffe F; Schaefer-Graf UM; Fauzan R; Schohe AL; Scholle D; Sedlacek L; Scherer KA; Klapp C; Ramsauer B; Henrich W; Schlembach D; Abou-Dakn M
    Diabet Med; 2019 Feb; 36(2):158-166. PubMed ID: 30698863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term body weight trajectories and metabolic control in type 1 diabetes patients on insulin pump or multiple daily injections: A 10-year retrospective controlled study.
    Alderisio A; Bozzetto L; Franco L; Riccardi G; Rivellese AA; Annuzzi G
    Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1110-1117. PubMed ID: 31371264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT.
    Blair J; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes D; Gamble C
    Health Technol Assess; 2018 Aug; 22(42):1-112. PubMed ID: 30109847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of Continuous Subcutaneous Insulin Infusion and Multiple Daily Injections in Pediatric Type 1 Diabetes: A Meta-Analysis and Prospective Cohort Study.
    Wang X; Zhao X; Chen D; Zhang M; Gu W
    Front Endocrinol (Lausanne); 2021; 12():608232. PubMed ID: 33737909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Assessment of metabolic control and safety of continuous subcutaneous insulin infusion in prepubertal children with type 1 diabetes mellitus].
    Minkina-Pedras M; Jarosz-Chobot P; Małecka-Tendera E; Deja G
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2005; 11(3):171-6. PubMed ID: 16232370
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM.
    Attia N; Jones TW; Holcombe J; Tamborlane WV
    Diabetes Care; 1998 May; 21(5):817-21. PubMed ID: 9589247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pregnancy Outcomes and Insulin Requirements in Women with Type 1 Diabetes Treated with Continuous Subcutaneous Insulin Infusion and Multiple Daily Injections: Cohort Study.
    Abell SK; Suen M; Pease A; Boyle JA; Soldatos G; Regan J; Wallace EM; Teede HJ
    Diabetes Technol Ther; 2017 May; 19(5):280-287. PubMed ID: 28282241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of continuous subcutaneous insulin infusion on insulin binding to erythrocytes in diabetes mellitus.
    Ng FM; Babacan E; Cohen M; Zimmet PZ
    Diabetes Res Clin Pract; 1987; 3(1):31-7. PubMed ID: 3545728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) in paediatric Type 1 diabetes: a multicentre matched-pair cohort analysis over 3 years.
    Jakisch BI; Wagner VM; Heidtmann B; Lepler R; Holterhus PM; Kapellen TM; Vogel C; Rosenbauer J; Holl RW;
    Diabet Med; 2008 Jan; 25(1):80-5. PubMed ID: 18199134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IMPROVED HBA1C, TOTAL DAILY INSULIN DOSE, AND TREATMENT SATISFACTION WITH INSULIN PUMP THERAPY COMPARED TO MULTIPLE DAILY INSULIN INJECTIONS IN PATIENTS WITH TYPE 2 DIABETES IRRESPECTIVE OF BASELINE C-PEPTIDE LEVELS.
    Vigersky RA; Huang S; Cordero TL; Shin J; Lee SW; Chhabra H; Kaufman FR; Cohen O;
    Endocr Pract; 2018 May; 24(5):446-452. PubMed ID: 29847166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality of life and metabolic control in patients with diabetes mellitus type 1 treated by continuous subcutaneous insulin infusion or multiple daily insulin injections.
    Hoogma RP; Spijker AJ; van Doorn-Scheele M; van Doorn TT; Michels RP; van Doorn RG; Levi M; Hoekstra JB
    Neth J Med; 2004 Nov; 62(10):383-7. PubMed ID: 15683093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of continuous subcutaneous insulin infusion with multiple insulin injections using the NovoPen.
    Saurbrey N; Arnold-Larsen S; Møller-Jensen B; Kühl C
    Diabet Med; 1988 Mar; 5(2):150-3. PubMed ID: 2964981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.